Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of genetically proxied plasma sclerostin levels on the risk of ischemic stroke: A drug-target Mendelian randomization study.

Medicine - 20 Mar 2026

Lee Woo Vin, Oh Jung Mi, Kim In-Wha

Abstract excerpt

Evidence of a causal link between sclerostin-lowering interventions and ischemic stroke remains uncertain due to the limitations of previous observational studies and the post hoc analyses of randomized trials. Therefore, this study aims to investigate the causal effect of plasma sclerostin abundance on incident ischemic stroke and its subtypes. To do this, we conducted a drug-target Mendelian randomization...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Bayes Theorem

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Markers

Share to Ischemic Stroke

Share to Linkage Disequilibrium

Share to Mendelian Randomization Analysis

Share to Polymorphism, Single Nucleotide

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 41861221
DOI: 10.1097/MD.0000000000048014
PMCID: PMC13008229

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of genetically proxied plasma sclerostin levels on the risk of ischemic stroke: A drug-target Mendelian randomization study.PMID 41861221Read ↗

Systematic Druggable Genome-Wide Mendelian Randomization Identifies Therapeutic Targets for Functional Outcome After Ischemic Stroke.Semantic proximity Read ↗

Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization.Semantic proximity Read ↗

Mendelian Randomization in Stroke: A Powerful Approach to Causal Inference and Drug Target ValidationSemantic proximity Read ↗

Mendelian Randomization Studies in Stroke: Exploration of Risk Factors and Drug Targets With Human Genetic Data.Semantic proximity Read ↗

Leveraging Mendelian randomization to inform drug discovery and development for ischemic strokeSemantic proximity Read ↗

Mendelian randomization study of lithocholate sulfate mediating the effect of MMP-1 on ischemic stroke.Semantic proximity Read ↗

LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization StudySemantic proximity Read ↗

Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomizationSemantic proximity Read ↗

Genetically Determined Plasma Hepatocyte Growth Factor Levels Are Associated With the Risk and Prognosis of Ischemic Stroke.Semantic proximity Read ↗

Causal associations of serum matrix metalloproteinase-8 level with ischaemic stroke and ischaemic stroke subtypes: a Mendelian randomization study.Semantic proximity Read ↗

Causal Effect of Lipoprotein-Associated Phospholipase A2 Activity on Ischemic Stroke: A Mendelian Randomization Study.Semantic proximity Read ↗

Sodium-glucose cotransporter protein 2 inhibition, plasma proteins, and ischemic stroke: A mediation Mendelian randomization and colocalization study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.